Provenge Receives A Positive National Determination from CMS
Yesterday Dendreon, the producers of Provenge, received word from the FDA that their plant in California had been approved to manufacture Provenge. This afternoon they received a positive response from the Centers for Medicare and [...]
Dendreon Receives Approval for Their New Plant in California
Early this evening Dendreon received the nod from the FDA to use their new manufacturing plant in Seal Beach, California. The approval of this plant will allow the company to now service the men with [...]
Malecare Responds to the New York Times About the High Costs of Advanced Prostate Cancer Treatments
Darryl, the Malecare Executive Director, posted an organizational response to yesterday's New York Times Article on the newly approved advanced prostate cancer drugs and their economic impact. I thought that I would share his insightful [...]
The High Cost of Prostate Cancer Treatments – How Telling Are the Comments
Today’s New York Times carried a front page article about the high cost of the new prostate cancer treatments. This article seems to be the talk of the town and the talk (based on the [...]
On The Horizon – Xgeva (denosumab) To Prevent or Slow Down Bone Mets
Yesterday, Amgen announced that it had submitted a supplemental Biologics License Application (sBLA) to the U.S. Food and Drug Administration (FDA) to expand its license for XGEVA® (denosumab) to treat men with castrate-resistant prostate cancer [...]
Tell the World About Malecare and Improve Our Exposure
Dear Friends, If you love the work of Malecare Cancer Support, then tell the world! You may or may not realize it, but Malecare has grown to become America's largest men's cancer survivor support and [...]